drugset / Trial / NCT00185614
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish mixed chimerism using low dose total body irradiation along with immunosuppression using cyclosporine and mycophenolate mofetil; suppress graft-vs-host and host-vs-graft reactions to allow a mixed chimeric state to be established, encourage tolerance and prevent graft-vs-host disease (GvHD) during the mixed chimerism period and use donor lymphocyte infusions to convert the patient to a full chimera while developing a graft-vs-tumor effect.
Timeline
- Start
- 2000-08
- Primary completion
- 2009-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | 4 g | Intravenous |
| Background | Melphalan | Small molecule | 200 mg/m2 | Intravenous |
| Background | Mycophenolate mofetil (MMF) | Unknown | 15 mg/kg | Oral |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | — |
| Background | filgrastim | Protein / enzyme biologic | 10 ug/kg | — |
| Background | filgrastim | Protein / enzyme biologic | 16 ug/kg | — |